4/1
Positive
Early treatment study
et al., Journal of Molecular Cell Biology, Volume 12, Issue 4, April 2020, 322–325, doi:10.1093/jmcb/mjaa014 (Peer Reviewed)
Treating COVID-19 with Ch loroquine
22 patients. All C Q patients discharged by day 14 versus 50% of Lopinavir/Rotinavir patients. Symptom onset to treatment 2.5 days for C Q vs. 6.5 days for Lopinavir/Rotinavir.
no recovery, ↓90.9%, p=0.09, risk of no recovery at day 14
no improvement in pneumonia, ↓83.0%, p=0.22, risk of no improvement in pneumonia at day 14
no improvement in pneumonia, ↓83.0%, p=0.22, risk of no improvement in pneumonia at day 14